Reinventing the heart valve

Xeltis is a clinical-stage company developing medical devices enabling cardiovascular restoration.

Xeltis’ technology platform, RestoreX, comprises the first-ever bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR): the natural restoration of the complex body part they replace upon implantation.

Potentially addressing 100,000s
patients / year
The RestoreX innovative technology platform comprises a number of potential applications to cardiovascular conditions and patient populations.

Xeltis closed a $33 Million Series B Financing ($30 million in 2014, extended by $3 million in 2015) supporting clinical evaluation and market development for its innovative technology.

“Xeltis has the potential to transform the way heart valve disease is treated in the future.”

- Michel Darnaud, Chairman of the Board of Xeltis

Xeltis is accelerating progression

  • Swiss Xeltis founded as Univeristy of Zurich spin-off
  • Xeltis merges with Dutch Qtis/e, becoming today’s Xeltis
  • Feasibility clinical trials start (patch and conduit)
  • Series B financing round closed
  • Executive team expands, team reaches 30+
  • Series B financing extended
  • 2-year clinical data on bioabsorbable cardiovascular technology presented at EACTS
  • Pulmonary valve, first commercial product, enters clinical trial phase
  • International Clinical and Scientific Advisory Boards set-up
  • Aortic valve enters preclinical trial phase
  • US FDA approved Investigational Device Exemption (IDE) for PV Early Feasibility Study (EFS)

Xeltis has been recognized as a breakthrough medtech start-up


Top-25 Tech-tour Medtech Summit 2012


Promising Start-up by IMD Business School


Biovision Next Gem Award 2013


Out-of-the-box technology at PCR 2015


Fierce 15 list by Fierce Medical Devices 2015

XELTIS CEO, Laurent Grandidier
  • Included in the 2016 100 Power List by Medicine Maker
  • Nominated 2015 Best CEO in the Medical Device Industry by magazine European CEO